Fax: (717) 531-0882
A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer
Implications for adjuvant therapy
Version of Record online: 7 FEB 2008
Copyright © 2008 American Cancer Society
Volume 112, Issue 7, pages 1547–1554, 1 April 2008
How to Cite
Varlotto, J. M., Flickinger, J. C., Recht, A., Nikolov, M. C. and DeCamp, M. M. (2008), A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer. Cancer, 112: 1547–1554. doi: 10.1002/cncr.23289
- Issue online: 19 MAR 2008
- Version of Record online: 7 FEB 2008
- Manuscript Accepted: 2 OCT 2007
- Manuscript Revised: 29 SEP 2007
- Manuscript Received: 19 APR 2007
- bronchioloalveolar carcinoma;
- disease-free survival;
- nonsmall cell carcinoma;
- lymph node-positive
The objective of this study was to assess whether disease-specific survival (DSS) and overall survival (OS) differed among patients who had N1 and N2 bronchioloalveolar carcinoma (BAC) compared with patients who had non-BAC nonsmall cell lung cancer (NSCLC).
The Surveillance, Epidemiology, and End Results (SEER) Program database from 1992 to 2002 contained 684 patients with BAC and 9809 patients with non-BAC NSCLC who had N1/N2 tumors and who underwent a definitive surgical procedure. OS and DSS rates were compared according to potential prognostic factors, including the use of a matched-pair analysis.
The BAC patients with either pathologic N1 or N2 lymph node status were significantly more likely to be women, and nonblack/nonwhite race, but significantly less likely to have poorly differentiated or undifferentiated tumors than patients with non-BAC cancers with comparable lymph node status. The median follow-up of all patients was 29 months. There was a significant difference in DSS between patients with N2 BAC and non-BAC cancers, but not for patients with N1 disease. There was a nonsignificant trend toward longer OS for patients with N2 BAC compared with non-BAC cancers.
Patients with lymph node-positive BAC had distinctly different patient and tumor characteristics than patients with lymph node-positive non-BAC NSCLC. Because DSS appears to be better for patients with N2 BAC, they may not benefit as much from adjuvant therapy as patients with non-BAC NSCLC. Cancer 2008. ©2008 American Cancer Society.